Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of BIIL 284 BS on Theophylline PK in Healthy Volunteers
NCT02273440Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2000
- Primary completion
- Jul 2000
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial in cystic fibrosis (CF) and rheumatoid arthritis (RA) comparing BIIL 284 BS + Theophylline with Placebo + Theophylline (2 arms). Primary endpoints: Plasma levels of theophylline up to 72 hours, Area under the curve from zero extrapolated to infinity up to 72 hours and 1 more. Started May 2000; status: completed.
02
Drugs
amelubant
03
Conditions
cystic fibrosis (CF)rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02273440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02273440.